Why Minerva Neurosciences, Inc.’s (NERV) Stock Is Down 5.05%
As of Thursday, November 19, Minerva Neurosciences, Inc.’s NERV share price has dipped by 5.05%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Rosalio Madrigal
Michael Rose
Tudor Pop
Michael Rose
Michael Rose
| Share Statistics | NERV | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $99.7 | $203.5 | 23% |
|
| Shares Out (Mil) | 75.3 | 55.2 | 56% |
|
| Institutional Ownership | 99.1% | 93.3% | 84% |
|
| Float (Mil) | 36.4 | 40.4 | 39% |
|
| Beta | 0.01 | 1.05 | 6% |
|
| Avg Daily Volume (000s) | 158 | 569 | 41% |
|
| Price Change (52-week) |
(53.5%) | 38.8% | 20% |
|
| Growth | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (174.7%) | (10.7%) | 0% |
|
| EPS (5yr) | (147.7%) | 15.4% | 0 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | 56.4% | (15.7%) | 95% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | 1 | 1 | |
| Current EPS | ($0.180) | ($0.540) | ($0.420) | |
| Month Ago EPS | na | ($0.570) | ($0.420) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | na | ($0.570) | ($0.420) | |
| Year/Year Chg | (2.7%) | (98.4%) | (99.6%) | |
| Financials | NERV | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $40 | na |
|
| Net Income (TTM) (Mil) | ($291) | ($44) | 4% |
|
| EPS (TTM) | ($7.705) | ($1.400) | 6% |
|
| Operating Cash Flow (TTM) (Mil) | ($31) | ($35) | 12% |
|
| Net Cash Flow (TTM) (Mil) | na | $-0 | na |
|
| Long-Term Debt (Q1) (Mil) | $60 | $4 | 40% |
|
| Enterprise Value (Q1) (Mil) | $126 | $142 | 24% |
|
| Valuation | NERV | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 1.96 | na |
|
| P/E | na | 16.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | NERV | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.8%) | na |
|
| ROA | (460.3%) | (47.0%) | 0% |
|
| ROE | 440.3% | (51.8%) | 99% |
|
| Liabilities to Assets | 187.3% | 29.6% | 99% |
|
| F-Score | 2 | 3 | 7% |
|
Minerva Neurosciences, Inc. did not pass any screens on 11/20/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors